Latest Sucampo Pharmaceuticals (SCMP) Headlines
Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 3 mins ago
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Thomson Reuters ONE - Wed Mar 12, 7:01PM CDT
Sucampo Will Evaluate All Options for Path Forward
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 26 Annual ROTH Conference on Wednesday March 12, 2014 at 12:30 pm Pacific.
Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014
GlobeNewswire - Tue Mar 04, 9:00AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and the National Cherry Blossom Festival (Festival) today announced their ongoing partnership to support the historic celebration of Japan's gift of cherry trees. Built on a passion for science and dedicated to supporting good health, Sucampo is co-sponsoring with the Festival this year's "Step Into Spring" fitness program. This program features free exercise and wellness classes over the course of the three weeks during the Festival, encouraging a healthy lifestyle for all participants.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Why Sucampo Pharmaceuticals, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 11:34AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sucampo Pharmaceuticals , a...
Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Full Year Net Income Excluding Special Items of $9.4 Million, Up 94% over 2012 and Exceeds Guidance
UPS Honors Kansas Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 17 elite drivers from Kansas are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.
Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast
GlobeNewswire - Wed Feb 12, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the fourth quarter and full year ended December 31, 2013, on Wednesday, February 26, 2014, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.
Sucampo Pharmaceuticals Inc elects Peter Greenleaf as CEO
M2 - Tue Feb 11, 7:11AM CST
Biopharmaceutical company Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) revealed on Monday the addition of Peter Greenleaf as its chief executive officer, as well as a member of its board of directors with effect from 3 March 2014.
Sucampo Names Peter Greenleaf Chief Executive Officer
Thomson Reuters ONE - Mon Feb 10, 3:03PM CST
BETHESDA, Md., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced that Peter Greenleaf will join Sucampo as Chief Executive Officer ("CEO") and as a member of the Board of Directors ("Board") on March 3, 2014. Mr. Greenleaf, 43, brings to Sucampo more than 20 years of experience in commercialization and drug development in the biopharmaceutical industry.
Salix's sNDA on Relistor Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:40PM CST
Salix Pharmaceuticals announced disappointing news when the U.S. Food and Drug Administration (FDA) postponed the previously scheduled meeting on Mar 10-11 to consider the Supplemental New Drug Application (sNDA) for Relistor.
All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R) for Chronic Idiopathic Constipation
GlobeNewswire - Thu Feb 06, 5:45AM CST
Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), headquartered in Zug, Switzerland, announced today that all physicians in Switzerland are now able to prescribe AMITIZA(lubiprostone) for chronic idiopathic constipation (CIC), as a result of the revision of the reimbursement limitations by the Bundesamt fur Gesundheit (BAG), effective February 1, 2014.
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 5:45AM CST
Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will present, via "fireside chat" format, at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12 at 3:30 pm Eastern.
Uptrend Call Working As Sucampo Pharmaceuticals Stock Rises 37.8% (SCMP)
Comtex SmarTrend(R) - Wed Jan 29, 9:12AM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on October 18th, 2013 at $6.74. In approximately 3 months, Sucampo Pharmaceuticals has returned 37.83% as of today's recent price of $9.29.
Sucampo Pharmaceuticals (SCMP) Crumbles: Stock Falls by 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:30AM CST
Sucampo Pharmaceuticals saw a big move last session on pretty good volume with far more shares changing hands than in a normal session.
57.9% Return Seen to Date on SmarTrend Sucampo Pharmaceuticals Call (SCMP)
Comtex SmarTrend(R) - Tue Jan 21, 4:52PM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on October 18th, 2013 at $6.74. In approximately 3 months, Sucampo Pharmaceuticals has returned 57.86% as of today's recent price of $10.64.
Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 3 mins ago
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Thomson Reuters ONE - Wed Mar 12, 7:01PM CDT
Sucampo Will Evaluate All Options for Path Forward
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 ROTH Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 26 Annual ROTH Conference on Wednesday March 12, 2014 at 12:30 pm Pacific.
Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014
GlobeNewswire - Tue Mar 04, 9:00AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and the National Cherry Blossom Festival (Festival) today announced their ongoing partnership to support the historic celebration of Japan's gift of cherry trees. Built on a passion for science and dedicated to supporting good health, Sucampo is co-sponsoring with the Festival this year's "Step Into Spring" fitness program. This program features free exercise and wellness classes over the course of the three weeks during the Festival, encouraging a healthy lifestyle for all participants.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Why Sucampo Pharmaceuticals, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 11:34AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Sucampo Pharmaceuticals , a...
Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Full Year Net Income Excluding Special Items of $9.4 Million, Up 94% over 2012 and Exceeds Guidance
UPS Honors Kansas Drivers for 25 Years of Safe Driving
Business Wire - Wed Feb 19, 9:00AM CST
UPS (NYSE:UPS) today announced 17 elite drivers from Kansas are among 1,519 newly inducted worldwide into the Circle of Honor, an honorary organization for UPS drivers who have achieved 25 or more years of accident-free driving.
Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast
GlobeNewswire - Wed Feb 12, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the fourth quarter and full year ended December 31, 2013, on Wednesday, February 26, 2014, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.
Sucampo Pharmaceuticals Inc elects Peter Greenleaf as CEO
M2 - Tue Feb 11, 7:11AM CST
Biopharmaceutical company Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) revealed on Monday the addition of Peter Greenleaf as its chief executive officer, as well as a member of its board of directors with effect from 3 March 2014.
Sucampo Names Peter Greenleaf Chief Executive Officer
Thomson Reuters ONE - Mon Feb 10, 3:03PM CST
BETHESDA, Md., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced that Peter Greenleaf will join Sucampo as Chief Executive Officer ("CEO") and as a member of the Board of Directors ("Board") on March 3, 2014. Mr. Greenleaf, 43, brings to Sucampo more than 20 years of experience in commercialization and drug development in the biopharmaceutical industry.
Salix's sNDA on Relistor Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:40PM CST
Salix Pharmaceuticals announced disappointing news when the U.S. Food and Drug Administration (FDA) postponed the previously scheduled meeting on Mar 10-11 to consider the Supplemental New Drug Application (sNDA) for Relistor.
All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R) for Chronic Idiopathic Constipation
GlobeNewswire - Thu Feb 06, 5:45AM CST
Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), headquartered in Zug, Switzerland, announced today that all physicians in Switzerland are now able to prescribe AMITIZA(lubiprostone) for chronic idiopathic constipation (CIC), as a result of the revision of the reimbursement limitations by the Bundesamt fur Gesundheit (BAG), effective February 1, 2014.
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 5:45AM CST
Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will present, via "fireside chat" format, at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12 at 3:30 pm Eastern.
Uptrend Call Working As Sucampo Pharmaceuticals Stock Rises 37.8% (SCMP)
Comtex SmarTrend(R) - Wed Jan 29, 9:12AM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on October 18th, 2013 at $6.74. In approximately 3 months, Sucampo Pharmaceuticals has returned 37.83% as of today's recent price of $9.29.
Sucampo Pharmaceuticals (SCMP) Crumbles: Stock Falls by 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:30AM CST
Sucampo Pharmaceuticals saw a big move last session on pretty good volume with far more shares changing hands than in a normal session.
57.9% Return Seen to Date on SmarTrend Sucampo Pharmaceuticals Call (SCMP)
Comtex SmarTrend(R) - Tue Jan 21, 4:52PM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on October 18th, 2013 at $6.74. In approximately 3 months, Sucampo Pharmaceuticals has returned 57.86% as of today's recent price of $10.64.
